Abeona Therapeutics Inc. (ABEO) Stock Price Quote, News &…

Summary

Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.

Website

www.abeonatherapeutics.com

Location

Cleveland, OH, US

Phone646 813 4701

Employees226

CEOVishwas Seshadri

Sector

Health Care

Industry

Pharmaceuticals

IPO DateSep 19, 1980

Ask AI

Company overview

Business model, segments, and competition.

Peer comparison

Metrics vs closest competitors.

Guidance & outlook

Forward guidance and assumptions.

Bull vs bear case

Upside drivers and key risks.

Valuation snapshot

Multiples vs history and peers.

Competitive moat

Defensibility and market position.

Management track record

Leadership and capital allocation history.

How it makes money

A short diagram of the business model.

Latest Documents

Mentions in Filings

… under the UT Southwestern Agreement other than costs related to maintenance of patents. Abeona Rett Agreement On October 29, 2020, the Company entered into a license agreement (the “Abeona Rett Agreement”) with Abeona Therapeutics Inc. (“Abeona”) pursuant to which the Company obtained an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses under certain patents, know-how and materials originally developed by the Un …
Taysha Gene Therapies, Inc.Abeona Therapeutics Inc.·10-Q - Quarterly report Q3·Q3 26·12 Nov
… ract development and manufacturing organization, from inception in January 2020 through its acquisition by Ajinomoto and into September 2024. Prior to Forge, Dr. Miller was co-founder and Chief Executive Officer of Abeona Therapeutics (Nasdaq: ABEO), a gene therapy company, from 2013 to 2018 and President and Chief Science Officer from 2018 to 2020. Dr. Miller holds both a B.S. and M.S. in Biology from John Carroll University and a Ph.D. in pharm …
Research Alliance Corp IIIAbeona Therapeutics Inc.·424B4 - Prospectus filing (Rule 424(b)(4))·Q4 26·4 Nov
… ract development and manufacturing organization, from inception in January 2020 through its acquisition by Ajinomoto and into September 2024. Prior to Forge, Dr. Miller was co-founder and Chief Executive Officer of Abeona Therapeutics (Nasdaq: ABEO), a gene therapy company, from 2013 to 2018 and President and Chief Science Officer from 2018 to 2020. Dr. Miller holds both a B.S. and M.S. in Biology from John Carroll University and a Ph.D. in pharm …
OHB Pediatrics Ltd.Abeona Therapeutics Inc.·S-4/A - Registration statement (business combination, amendment)·Q4 26·30 Oct
… artis and Schering-Plough, where she contributed to the development and approvals of oncology therapies including Tagrisso®, Opdivo®, Tasigna® and Caelyx®. Dr. Alland currently serves on the Board of Directors of Abeona Therapeutics Inc. Dr. Alland received her medical degree from New York University and her bachelor’s degree from the University of Pennsylvania. She completed her pediatric training at The Children’s Hospital of Philadelphia and …
Cardiff Oncology, Inc.Abeona Therapeutics Inc.·EX-99.1 - 8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q4 26·27 Oct
… company focused on p53; Affimed, an immuno-oncology company; and Tarveda Therapeutics, a company developing targeted drug conjugates. Previously, she held leadership positions at AstraZeneca, Bristol Myers Squibb, Novartis and Schering-Plough, where she contributed to the development and approvals of oncology therapies including Tagrisso®, Opdivo®, Tasigna® and Caelyx®. Dr. Alland currently serves on the Board of Directors of Abeona Therapeutics.
Cardiff Oncology, Inc.Abeona Therapeutics Inc.·8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q4 26·27 Oct
… ial – 18 Months 33 10 MISSION EB-DELIVER Market Landscape: Comparison of Therapeutic Approaches Vyjuvek = Product of Krystal Biotech, Inc.; Filsuvez = Product of Chiesi Farmaceutici S.p.A.; Zevaskyn = Product of Abeona Therapeutics Inc. 34 The TAM is an estimate based on internal assumptions and third-party sources, is a forward-looking statement and does not guarantee any future performance. Actual TAM may differ materially. See "Disclaimer" an …
Inmune Bio, Inc.Abeona Therapeutics Inc.·EX-99.3 - 8-K - Regulation FD Disclosure·Q4 26·21 Oct

Key Stats

Trading

Px/Chg 1D$5.03 / +0.40%

Prev Close$6.00

% of 52Wk H76.47%

Avg Volume1.18M

Beta1.36

Mkt Cap286.69M

FD Mkt Cap333.42M

Float

Shrs Out/Float57.00M / 36.62M

Short Float0.37%

Days to Cover8.67

Stock Repurchased$0.00

Current Valuation

EV248.48M

EV/EBITDA3.38

EV/Sales17.09

P/B1.98

P/S19.72

FCF Yield-7.23%

ROE-11.78%

ROA-8.60%

Current Ratio5.89

Dividend

Cash$0.59

Yield8.55%

Yield (TTM)8.55%

Estimates

P/E4.33

Est P/E0.00

Est EPS-0.33

Est PEG0.00

Valuation

Metric	5Yr Avg	May '23	May '24	May '25	May '26	Oct '26
PRICE-BASED RATIOS
Price / Earnings	-7.46	-0.63	-1.66	-3.47	-14.70	-16.84
Price / Sales	26.38	17.79	25.66	0.00	55.49	32.97
Price / Book Value	3.18	0.94	6.06	5.02	1.89	1.98
Price / Free Cash Flow	-7.27	-0.58	-2.40	-3.78	-15.74	-13.86
ENTERPRISE VALUE METRICS
Enterprise Value	163.4	18.6	80.7	220.9	247.3	249.3
Enterprise Value / Sales	22.08	13.13	23.06	0.00	45.63	28.59
Enterprise Value / EBITDA	-7.10	-0.54	-1.60	-3.90	-13.23	-16.22
Enterprise Value / EBIT	-6.71	-0.48	-1.50	-3.71	-12.50	-15.35

Financials

Full Financials

Millions USD	5Yr CAGR (%)	Dec '21	Dec '22	Dec '23	Dec '24	Dec '25
INCOME STATEMENT
Revenue	18%	3.0	1.4	3.5	-	5.8
Gross Income	9.3%	3.0	1.0	1.9	-2.9	4.3
EBITDA	—	-76.8	-34.4	-50.6	-56.6	78.6
EBIT	—	-81.3	-39.0	-53.8	-59.5	75.0
Net Income	—	-84.9	-39.7	-54.2	-63.7	71.2
EPS (Diluted)	—	-21.50	-5.53	-2.53	-1.55	1.01
BALANCE SHEET
Cash & ST Inv	43.6%	45.0	52.1	52.2	97.7	191.4
Total Assets	28.9%	79.6	64.2	64.0	108.9	219.6
Total Liabilities	12.8%	37.2	37.5	49.2	64.9	60.4
Total Shareholder Equity	39.2%	42.4	26.8	14.8	44.0	159.2
CASH FLOW
Net Operating Cash Flow	3.8%	-65.7	-43.5	-37.0	-56.0	-76.3
Cap Ex	17.7%	-4.2	-0.1	-0.3	-2.4	-8.0
Free Cash Flow	4.8%	-69.8	-43.6	-37.3	-58.5	-84.3

Enterprise Value Bridge

Millions USD		13 Nov '26
Price (As of 13 Nov '26)		2.42
Basic Shares		57.00
Market Cap		137.6
Diluted Shares		57.05
Fully Diluted Shares Outstanding		57.05
Fully Diluted Market Cap		137.8
+Consolidated Debt		19.9
−In-the-Money Convertible Debt		—
+Capital Leases		4.9
+Operating Leases		—
−Cash & Equivalents		-56.2
−Short-term Investments		-90.6
+Total Preferred		-
−In-the-Money Convertible Preferred		—
−Investments in Unconsolidated Subs		—
+Non-Controlling Interest		-
+Pension Liabilities		—
Enterprise Value		101.3

Segment data

Revenue

by Products and services

License58%
Product42%

Related companies